<DOC>
	<DOC>NCT02204501</DOC>
	<brief_summary>The primary aim of this Phase 1 study is to evaluate the effect of vapendavir daily doses of 528 mg daily (QD) and 264 mg twice daily (BID) on the pharmacokinetic (PK) profile of midazolam, a cytochrome (CYP) 3A4 substrate. Additionally, the effect of midazolam on the PK profile of vapendavir, a PK profile comparison of vapendavir in males and females, as well as the safety of vapendavir will also be assessed.</brief_summary>
	<brief_title>A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Must be male or female between 18 and 55 years of age (inclusive) with BMI between 18 and 30 kg/m2 (inclusive), and weight â‰¥50 kg at the time of screening; Capable of giving written informed consent; Subject is able to understand and comply with the protocol requirements, instructions and restrictions; Healthy on the basis of physical examination, medical history, medication usage, vital signs (VS), electrocardiograms (ECGs), and clinical laboratory tests; Female subjects who are not postmenopausal for at least 2 years or surgically sterile with complete hysterectomy or bilateral oophorectomy and male subjects who are not surgically sterile via vasectomy, must agree to use a double barrier method of birth control, such as a condom plus spermicidal agent (foam/gel/film/cream/suppository); and Female subjects must not be breastfeeding or pregnant. Positive results for Hepatitis B, Hepatitis C, or HIV; Frequent use (defined as &gt; 5 times/day) of tobacco products, including cigarettes, cigars, chewing tobacco; A medical history of significant hematological, gastrointestinal, respiratory, renal, hepatic, cerebrovascular, immunologic, psychiatric or cardiovascular disease or event; Current or recent respiratory infection (defined as within 14 days of first study visit participation) Presence or history of significant allergy; Clinically significant abnormalities noted on ECG; Screening vital signs representing sustained elevated systolic blood pressure &lt;90 mmHg or &gt;140 mmHg, and/or diastolic blood pressure &lt;55 mmHg or &gt;90 mmHg. Presence of significant gastrointestinal abnormalities such as diarrhea or constipation; Safety laboratory abnormalities noted at screening which are clinically significant Current or defined history of abuse of alcohol or illicit drugs; A positive pregnancy test at screening; Poor vein access or fear of venipuncture or sight of blood; and Regular consumption of alcohol defined as either &gt; 2 units (glass or shot) of alcoholic beverages per day or &gt; 14 units per week.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Aviragen Therapeutics, Inc.</keyword>
	<keyword>Aviragen Therapeutics</keyword>
	<keyword>Aviragen</keyword>
</DOC>